GILD · 10-Q · 2026Q3

GILEAD SCIENCES, INC.

Filed 2026-10-30 · Healthcare · View original filing on EDGAR

Ranked Events

• Acquisition and Pipeline ExpansionImportance 71 · Surprise 60
  During the second quarter of 2026, Gilead completed acquisitions of Arcellx, Tubulis and Ouro Medicines, adding oncology and inflammation assets and capabilities. The filing reports acquired in-process R&D expenses of…
• Acquisition and RestructuringImportance 65 · Surprise 60
  Acquired in-process research and development expenses totaled $11.3 billion for the nine months ended September 30, 2026, primarily reflecting $7.0 billion for Arcellx, $3.1 billion for Tubulis and $1.0 billion net for…
• Medicare Drug Price NegotiationImportance 48 · Surprise 48
  In October 2026, the Centers for Medicare and Medicaid Services completed setting the Maximum Fair Price for Biktarvy under Medicare. The negotiated price takes effect on January 1, 2028, and management states that it…
• Trodelvy Demand GrowthImportance 46 · Surprise 56
  Trodelvy product sales rose 42% to $506 million in the third quarter and 35% to $1.4 billion for the first nine months of 2026. Gilead attributed the growth in both periods primarily to higher demand. The filing also…
• Revenue Performance and MixImportance 43 · Surprise 32
  Total revenues increased 7% to $8.3 billion for the three months and $23.1 billion for the nine months ended September 30, 2026, compared with the same periods in 2025. Nine-month HIV product sales rose 14% to $17.0…
• Operating Expense TrendsImportance 40 · Surprise 48
  Selling, general and administrative expenses increased 21% to $1.6 billion for the three months ended September 30, 2026, and 26% to $5.0 billion for the nine months. Selling and marketing costs rose primarily because…
• Research and Development ExpenseImportance 35 · Surprise 40
  Research and development expenses increased 19% to $1.6 billion for the three months ended September 30, 2026, and increased 13% to $4.7 billion for the nine months. Nine-month personnel, infrastructure and support…
• Regulatory Approval MilestonesImportance 34 · Surprise 42
  Gilead received FDA approval for Bixlenvo for adults with HIV who are virologically suppressed on a stable antiretroviral regimen, and FDA accelerated approval for Hepcludex for chronic hepatitis delta virus infection…
• Oncology Product ExpansionImportance 34 · Surprise 42
  Trodelvy received European Commission authorization in combination with Keytruda for eligible first-line metastatic triple-negative breast cancer patients whose tumors express PD-L1. The FDA also approved Trodelvy for…
• HIV and PrEP Demand GrowthImportance 32 · Surprise 32
  HIV product sales increased 18% to $6.2 billion in the third quarter and 14% to $17.0 billion for the first nine months of 2026. Growth reflected higher demand and average realized prices, with favorable inventory…
• Liver Disease Sales GrowthImportance 26 · Surprise 32
  Liver Disease product sales increased 13% to $927 million in the third quarter and 8% to $2.6 billion for the first nine months of 2026. Higher demand for Livdelzi drove growth in both periods, with nine-month growth…
• Liquidity and Cash PositionImportance 25 · Surprise 24
  Cash and cash equivalents were $6.4 billion as of September 30, 2026. Net cash provided by operating activities increased to $11.152 billion for the nine months ended September 30, 2026, primarily due to lower income…
• In-Process R&D ImpairmentImportance 22 · Surprise 42
  Gilead recorded a $1.75 billion impairment charge during the nine months ended September 30, 2026, eliminating the remaining carrying value of its NSCLC in-process R&D intangible asset. The impairment followed the June…
• Cell Therapy CompetitionImportance 20 · Surprise 32
  Cell Therapy product sales declined 18% to $355 million in the third quarter and 15% to $1.2 billion in the first nine months of 2026. Gilead attributed the decreases to lower demand reflecting ongoing competitive…
• Gross Margin DriversImportance 18 · Surprise 32
  Product gross margin increased to 81.0% for the three months ended September 30, 2026, up 241 basis points from the prior-year period. For the nine months ended September 30, 2026, product gross margin was 79.9%, up…
• Product Launch and TransitionImportance 10 · Surprise 60
  Gilead received FDA approval for Bixlenvo, a complete single-tablet HIV regimen for virologically suppressed adults, including patients switching from complex multi-tablet regimens. FDA accepted a supplemental NDA for…
• Veklury Sales DeclineImportance 10 · Surprise 64
  Veklury product sales fell 69% to $86 million in the third quarter of 2026 and 64% to $253 million for the first nine months. The filing attributes the declines to lower rates of COVID-19-related hospitalizations. The…
• Income Tax Rate ChangesImportance 9 · Surprise 14
  The effective tax rate for the three months ended September 30, 2026, increased to 20.7% from 16.2% a year earlier, a 452-basis-point increase. The change primarily reflected a tax-authority settlement and…
• Quarterly Dividend DeclarationImportance 7 · Surprise 6
  In October 2026, Gilead’s board declared a quarterly dividend of $0.82 per common share. The dividend is payable December 30, 2026, to stockholders of record at the close of business on December 15, 2026. Future…

Revenue by Product (in millions)